Neovasc Inc. is offering up about $65 million worth of common shares and warrants that could help it handle litigation related to its Tiara mitral valve technology and clinical trials. The Vancouver-based company priced the underwritten offering of 6,609,588 series A units and 19,066,780 series B units, at a price of $1.46 per unit. Read More
